IMpower150 Study: Atezolizumab in Combination with Bevacizumab and Chemotherapy in EGFR-Mutated NSCLC

2020 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations.

Atezolizumab is a programmed cell death-ligand 1 inhibitor that may have enhanced efficacy in combination with bevacizumab, which inhibits vascular endothelial growth factor immunosuppression and promotes T-cell tumor infiltration. IMpower150 was a randomized phase 3 study that evaluated first-line treatment with atezolizumab and/or bevacizumab with carboplatin + paclitaxel in patients with nonsquamous non–small-cell lung cancer (NSCLC), including those with EGFR mutations. Previously reported results demonstrated that the addition of atezolizumab to bevacizumab in combination with carboplatin + paclitaxel significantly prolonged progression-free survival (PFS) and overall survival (OS). The researchers reported the results of the final efficacy analysis during the ESMO Virtual Congress 2020.

A total of 1202 patients were randomized to atezolizumab + bevacizumab + carboplatin/paclitaxel (ABCP); atezolizumab + carboplatin/paclitaxel (ACP); or bevacizumab + carboplatin/paclitaxel (BCP) for 4 or 6 cycles per investigator decision, followed by maintenance every 3 weeks with atezolizumab + bevacizumab, atezolizumab, or bevacizumab, respectively. A total of 123 patients had EGFR mutations, including 91 with a sensitizing mutation. The co-primary end points were OS and investigator-assessed PFS in the intention-to-treat (ITT)–wild-type population (which excluded patients with EGFR or ALK alterations). Exploratory analyses were performed for OS in patients with EGFR mutations, those with sensitizing EGFR mutations (exon 19 deletions or L858R mutations), and those with sensitizing EGFR mutations who received prior tyrosine kinase inhibitors (TKIs).

In the ITT population, median follow-up was 39.3 months (data cutoff, September 13, 2019). Among patients with EGFR mutations, the median OS was 26.1 months with ABCP, 21.4 months with ACP, and 20.3 months with BCP (hazard ratios [HRs] for ABCP vs BCP and ACP vs BCP were 0.91 [95% confidence interval (CI), 0.53-1.59] and 1.16 [95% CI, 0.71-1.89], respectively). Among patients with sensitizing EGFR mutations, the median OS was 29.4 months with ABCP, 19.0 months with ACP, and 18.1 months with BCP (HRs for ABCP vs BCP and ACP vs BCP were 0.60 [95% CI, 0.31-1.14] and 1.0 [95% CI, 0.57-1.74], respectively). Among patients who received prior TKI therapy, median OS was 27.8 months with ABCP, 14.9 months with ACP, and 18.1 months with BCP (HRs for ABCP vs BCP and ACP vs BCP were 0.74 [95% CI, 0.38-1.46] and 1.22 [95% CI, 0.68-2.22], respectively).

The researchers concluded that the addition of atezolizumab to bevacizumab in combination with carboplatin + paclitaxel continued to show improvement in OS and may provide a new option in patients with NSCLC and sensitizing EGFR mutations, including those who had prior treatment failure with TKIs.

Reference
Reck M, et al. ESMO 2020. 1293P.

 

Related Items
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Educating NSCLC Patients on Adverse Event Management
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T), Cathy Simmons, RN, BSN, ONN-CG(T), Lauren Welch, MSN, NP-C, AOCNP
Videos published on July 8, 2021 in Interview with the Innovators, Lung Cancer, Adverse Events
Addressing Lung Cancer Screening Disparities in LGBT Populations
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Analysis Identifies EGFR as Most Common Mutation in Women with Lung Cancer and No Smoking History
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Cemiplimab Potential New Treatment Option for Patients with Advanced NSCLC and PD-L1 ≥50%
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
“Astonishing Results” Seen with First-Line Lorlatinib for the Treatment of ALK-Positive NSCLC
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
Patients with BRAF V600E–Mutant NSCLC Show Improved Overall Survival with Dabrafenib + Trametinib Combination
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Last modified: July 22, 2021